Table 1.
Characteristics of the study population, treatments, and clinical outcomes.
| Characteristics | ||
|---|---|---|
| Variable | Total N = 14 | |
| Demographic characteristics and comorbidities | ||
| Age (years), median IQR | 69.5 | (45–81) |
| Male, n (%) | 11 | (78.6) |
| Charlson Comorbidity Index, median IQR | 5 | (0–10) |
| eGFR (mL/min/1.73 m2), median IQR | 68 | (32–122) |
| Albumin (g/dL), median IQR | 3.55 | (2.8–4.0) |
| Type of infection, n (%) | ||
| Prosthetic valve endocarditis | 8 | (57.1) |
| Prosthetic vascular grafts infections | 7 | (50) |
| Multiple site infection | 4 | (28.6) |
| Cardiac implantable electronic devices infections | 3 | (21.4) |
| Microbiological isolates, n (%) | ||
| Staphylococcus aureus | 5 | (35.7) |
| Methicillin-Sensitive Staphylococcus aureus | 4 | (28.6) |
| Viridans streptococcus | 3 | (21.4) |
| Coagulase-Negative stafilococci | 2 | (14.3) |
| Enterococcus faecalis | 1 | (7.1) |
| Gemella morbillorum | 1 | (7.1) |
| Corynebacterium striatum | 1 | (7.1) |
| Polymicrobial | 1 | (7.1) |
| Unknown | 1 | (7.1) |
| Treatment characteristics | ||
| Antibiotic first regimens, n (%) | ||
| Daptomycin | 4 | (28.6) |
| Ceftriaxone | 4 | (28.6) |
| Oxacillin | 3 | (21.4) |
| Rifampicin | 3 | (21.4) |
| Vancomycin | 2 | (14.3) |
| Doxycycline | 1 | (7.1) |
| Cefazoline | 1 | (7.1) |
| Gentamycin | 1 | (7.1) |
| Cefotaxime | 1 | (7.1) |
| Ampicillin | 1 | (7.1) |
| First line antibiotic median duration (weeks), median IQR | 3 | (1–5) |
| Reason for dalbavancin administration, n (%) | ||
| Facilitate discharge | 11 | (78.6) |
| Adverse events | 2 | (14.3) |
| Poor compliance to therapy | 1 | (7.1) |
| Median duration of dalbavancin therapy (weeks), median IQR | 13 | (5–49) |
| Median duration of dalbavancin therapy for indications, median IQR | ||
| Cardiac implantable electronic devices infections (CEDIs) | 25 | (9–53) |
| Prosthetic vascular grafts infections (PVGI) | 18.5 | (13–46) |
| Prosthetic valve endocarditis (PVEs) | 13 | (7–46) |
| Dalbavancin dosages and monitoring, n (%) | ||
| TDM | 9/14 | (64.3) |
| Dalbavancin regimens, n (%) | ||
| 1500 mg + 1500 mg, then according TDM | 7 | (50) |
| 1500 mg +1500 mg | 4 | (28.6) |
| 1500 mg + 1500 mg then 1000 mg every 14 d | 3 | (21.4) |
| Clinical outcomes | ||
| Complete source control with implant removal, n (%) | 4/14 | (28.6) |
| Median follow-up (weeks), median IQR | 65 | (23–144) |
| Clinical cure at the EOT (n = 13) | 10/13 | (76.9) |
| Clinical cure at six months of follow-up (n = 12) | 9/12 | (75) |
| Clinical cure in TDM-guided group (n = 8) | 7/8 | (87.5) |
| Microbiological cure at the EOT (n = 13) | 10/13 | (76.9) |
| Microbiological relapse after treatment interruption (n = 13) | 1/13 | (8.3) |
| Clinical cure by dalbavancin indications at the EOT, n (%) | ||
| Prosthetic valve endocarditis (n = 8) | 6/8 | (75) |
| Prosthetic vascular grafts infections (n = 6) | 5/6 | (83.3) |
| Cardiac implantable electronic devices infections (n = 3) | 2/3 | (66.6) |
| Adverse effect reactions | ||
| Rash, n (%) | 1 | (7.1) |
| Impaired renal function, n (%) | 1 | (7.1) |
Abbreviations: IQR, interquartile range; eGFR, estimated glomerular filtration calculated by means of the CKD-EPI formula; TDM, Therapeutic Drug Monitoring; EOT, end of treatment.